atezolizumab,trastuzumab,pertuzumab,trastuzumab emtansine
roche,daiichi sankyo
presented at #esmo vp6, impassion050 is now published on jco. the addition of atezo to neoadjuvant ddac-t+hp doesn t increase pcr rates in her2+ ebc, neither in itt (left) nor pd-l1+ (right). significant increase in toxicity with atezo, including 5 deaths. 
MD, Research Fellow @DanaFarber | @harvardmed | @IEOufficiale | @LaStatale. Interested in breast oncology, HER2, ADCs & good music. Coffee expert.